drugset / Trial / NCT03619187
An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
NaSingle-groupOpen-labelSupportive care
Summary
The hypothesis is that the treatment with ivabradine will increase pVO2 after 16 weeks of treatment compared to baseline in the heart transplant recipient population with elevated resting HR.
Timeline
- Start
- 2018-11-02
- Primary completion
- 2020-02-19
- Completion
- 2020-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivabradine | Small molecule | 2.5 mg | — |
| Subject | Ivabradine | Small molecule | 5 mg | — |
| Subject | Ivabradine | Small molecule | 7.5 mg | — |
Indications
No indication recorded.